12-month Prevalence Estimates of Substance Use Disorders Using DSM-5 Versus DSM-IV Criteria Among U.S. Nonelderly Adults With Substance Use

Wilson M. Compton,Emily B. Einstein,Beth Han

DOI: https://doi.org/10.1176/appi.ajp.20231060

IF: 17.7

2024-11-03

American Journal of Psychiatry

Abstract:American Journal of Psychiatry, Volume 181, Issue 11, Page 1018-1021, November 01, 2024.

psychiatry

What problem does this paper attempt to address?

DSM-5 Substance Use Disorders among Adult Primary Care Patients: Results from a Multisite Study.

Li-Tzy Wu,Jennifer McNeely,Geetha A. Subramaniam,Kathleen T. Brady,Gaurav Sharma,Paul VanVeldhuisen,He Zhu,Robert P. Schwartz

DOI: https://doi.org/10.1016/j.drugalcdep.2017.05.048

IF: 4.852

2017-01-01

Drug and Alcohol Dependence

Abstract:BACKGROUND: There are limited data about the extent of DSM-5 substance use disorders (SUDs) among primary care patients. METHODS: This study analyzed data from a multisite validation study of a substance use screening instrument conducted in a diverse sample of 2000 adults aged >= 18 years recruited from five primary care practices in four states. Prevalence and correlates of 12-month DSM-5 SUDs were examined. RESULTS: Overall, 75.5% of the sample used any substance, including alcohol (62.0%), tobacco (44.1%), or illicit drugs/nonmedical medications (27.9%) in the past 12 months (marijuana 20.8%, cocaine 7.3%, opioids 4.8%, sedatives 4.1%, heroin 3.9%). The prevalence of any 12-month SUD was 36.0% (mild disorder 14.2%, moderate/severe disorder 21.8%): tobacco 25.3% (mild 11.5%, moderate/severe 13.8%); alcohol 13.9% (mild 6.9%, moderate/severe 7.0%); and any illicit/nonmedical drug 14.0% (mild 4.0%, moderate/severe 10.0%). Among past 12-month users, a high proportion of tobacco or drug users met criteria for a disorder: tobacco use disorder 57.4% (26.1% mild, 31.3% moderate/severe) and any drug use disorder 50.2% (14.3% mild, 35.8% moderate/severe); a lower proportion of alcohol users (22.4%) met criteria for alcohol use disorder (11.1% mild, 11.3% moderate/severe). Over 80% of adults with opioid/heroin use disorder met criteria for a moderate/severe disorder. Younger ages, male sex, and low education were associated with increased odds of having SUD. CONCLUSION: These findings reveal the high prevalence of SUDs in primary care and underscore the need to identify and address them.
Implications of the shift to DSM‐5 for alcohol use disorder prevalence estimates in the National Survey on Drug Use and Health

Allen J. Bailey,Patrick D. Quinn,R. Kathryn McHugh

DOI: https://doi.org/10.1111/add.16670

2024-09-11

Addiction

Abstract:Background and aims The Substance Abuse and Mental Health Services Administration's annual National Survey on Drug Use and Health (NSDUH) is a commonly used source for estimating trends in alcohol use disorders (AUD) in the United States. From 2015 to 2019 the annual prevalence of people diagnosed with either Diagnostic and Statistical Manual 4th edition (DSM‐IV) alcohol abuse or dependence ranged from 5.3 to 5.9%. More recent estimates, using the DSM 5th edition (DSM‐5) AUD diagnostic formulation, have been higher, with AUD base rates ranging from 10.1 to 10.7% from 2020 to 2022. This study aimed to compare the past 12‐month base rates of AUD in the United States general population when using the DSM‐5 versus DSM‐IV AUD (i.e. abuse or dependence) and assess the AUD severity of individuals captured with each diagnostic formulation using DSM‐5 AUD symptom counts. Methods We examined descriptive trends in the rate of past‐year NSDUH AUD diagnoses from 2015 to 2022. We contrasted them with trends in drinking behavior: the percentage of individuals who had ever reported drinking and the number of drinking days and binge drinking days for those who drink. We also analyzed the concordance between DSM‐IV and DSM‐5 AUD diagnoses in the 2020 NSDUH, which concurrently assessed AUD with both diagnostic formulations. Results The transition to DSM‐5 AUD formulation coincided with a drastic increase in AUD prevalence rates that occurred without increases in drinking behavior. In 2020 NSDUH data, the estimated past‐year DSM‐5 AUD prevalence rate was 10.1% compared with a 5.4% rate of past‐year DSM‐IV abuse or dependence. The DSM‐5 AUD formulation captured more mild‐severity individuals than the DSM‐IV formulation. Conclusions Higher recent base rates of alcohol use disorders (AUD) in the National Survey on Drug Use and Health are likely, at least partially, explained by measurement changes in AUD; specifically, the shift from DSM‐IV abuse or dependence to DSM‐5 AUD. The DSM‐5 formulation appears substantially more inclusive than the DSM‐IV formulation, leading to a larger number of mild severity individuals being captured.

psychiatry,substance abuse
A Cross-National Examination of Differences in Classification of Lifetime Alcohol Use Disorder Between DSM-IV and DSM-5: Findings from the World Mental Health Survey

Tim Slade,Wai-Tat Chiu,Meyer Glantz,Ronald C Kessler,Luise Lago,Nancy Sampson,Ali Al-Hamzawi,Silvia Florescu,Jacek Moskalewicz,Sam Murphy,Fernando Navarro-Mateu,Yolanda Torres de Galvis,Maria Carmen Viana,Miguel Xavier,Louisa Degenhardt

DOI: https://doi.org/10.1111/acer.13134

Abstract:Background: The current study sought to examine the diagnostic overlap in DSM-IV and DSM-5 alcohol use disorder (AUD) and determine the clinical correlates of changing diagnostic status across the 2 classification systems. Methods: DSM-IV and DSM-5 definitions of AUD were compared using cross-national community survey data in 9 low-, middle-, and high-income countries. Participants were 31,367 respondents to surveys in the World Health Organization's World Mental Health Survey Initiative. The Composite International Diagnostic Interview, version 3.0, was used to derive DSM-IV and DSM-5 lifetime diagnoses of AUD. Clinical characteristics, also assessed in the surveys, included lifetime DSM-IV anxiety; mood and drug use disorders; lifetime suicidal ideation, plan, and attempt; general functional impairment; and psychological distress. Results: Compared with DSM-IV AUD (12.3%, SE = 0.3%), the DSM-5 definition yielded slightly lower prevalence estimates (10.8%, SE = 0.2%). Almost one-third (n = 802) of all DSM-IV abuse cases switched to subthreshold according to DSM-5 and one-quarter (n = 467) of all DSM-IV diagnostic orphans switched to mild AUD according to DSM-5. New cases of DSM-5 AUD were largely similar to those who maintained their AUD across both classifications. Similarly, new DSM-5 noncases were similar to those who were subthreshold across both classifications. The exception to this was with regard to the prevalence of any lifetime drug use disorder. Conclusions: In this large cross-national community sample, the prevalence of DSM-5 lifetime AUD was only slightly lower than the prevalence of DSM-IV lifetime AUD. Nonetheless, there was considerable diagnostic switching, with a large number of people inconsistently identified across the 2 DSM classifications.
Mental and Substance Use Disorders Prevalence Study: Background and Methods

Heidi Guyer,Heather Ringeisen,Jill Dever,Dan Liao,Andy Peytchev,Christine Carr,Paul Geiger,Leyla Stambaugh,Tim Smith,Lisa Dixon,Mark Olfson,Michael First,Scott Stroup,Lydia Chwastiak,Maria Monroe‐Devita,Jeff Swanson,Marvin Swartz,Ronald C. Kessler,Robert Gibbons,Natalie Bareis,Elizabeth Sinclair Hancq,Thomas Clarke,Mark Edlund,the MDPS Consortium

DOI: https://doi.org/10.1002/mpr.2000

2024-01-24

International Journal of Methods in Psychiatric Research

Abstract:Abstract Objective The Mental and Substance Use Disorders Prevalence Study (MDPS) builds upon previous epidemiologic studies to provide estimates of prevalence and treatment rates of mental and substance use disorders among adults aged 18–65 in the U.S. The study background and methods are described. Method The MDPS employed novel techniques such as the inclusion of household, prison, homeless and state psychiatric hospital populations, a semi‐structured clinical interview administered by trained clinical interviewers to assess disorders, the assessment of both past year and lifetime schizophrenia spectrum disorder (SSD) using full Diagnostic and Statistical Manual 5 criteria, as well as other mental and substance use disorders, and video‐based interviewing. Population specific and combined sample weights were developed to estimate nationally representative prevalence and treatment rates. Results Data collection was conducted between October 2020 and October 2022 resulting in 5679 clinical interviews. The statistical weighting and analytic plan are described. Weighted response rates and reasons for non‐response are provided for each study population. Conclusions The MDPS successfully developed and employed novel techniques to estimate the prevalence and treatment rates of mental and substance use disorders in both household and non‐household populations, including some of the most impairing disorders such as SSD.

psychiatry
The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services

D A Regier,W E Narrow,D S Rae,R W Manderscheid,B Z Locke,F K Goodwin

DOI: https://doi.org/10.1001/archpsyc.1993.01820140007001

Abstract:After initial interviews with 20,291 adults in the National Institute of Mental Health Epidemiologic Catchment Area Program, we estimated prospective 1-year prevalence and service use rates of mental and addictive disorders in the US population. An annual prevalence rate of 28.1% was found for these disorders, composed of a 1-month point prevalence of 15.7% (at wave 1) and a 1-year incidence of new or recurrent disorders identified in 12.3% of the population at wave 2. During the 1-year follow-up period, 6.6% of the total sample developed one or more new disorders after being assessed as having no previous lifetime diagnosis at wave 1. An additional 5.7% of the population, with a history of some previous disorder at wave 1, had an acute relapse or suffered from a new disorder in 1 year. Irrespective of diagnosis, 14.7% of the US population in 1 year reported use of services in one or more component sectors of the de facto US mental and addictive service system. With some overlap between sectors, specialists in mental and addictive disorders provided treatment to 5.9% of the US population, 6.4% sought such services from general medical physicians, 3.0% sought these services from other human service professionals, and 4.1% turned to the voluntary support sector for such care. Of those persons with any disorder, only 28.5% (8.0 per 100 population) sought mental health/addictive services. Persons with specific disorders varied in the proportion who used services, from a high of more than 60% for somatization, schizophrenia, and bipolar disorders to a low of less than 25% for addictive disorders and severe cognitive impairment. Applications of these descriptive data to US health care system reform options are considered in the context of other variables that will determine national health policy.
Characterizing Schizophrenia Spectrum Disorders: Results of the U.S. Mental and Substance Use Disorders Prevalence Study

Natalie Bareis,Mark Edlund,Heather Ringeisen,Heidi Guyer,Lisa B Dixon,Mark Olfson,Thomas E Smith,Lydia Chwastiak,Maria Monroe-DeVita,Marvin Swartz,Jeffrey Swanson,Elizabeth Sinclair Hancq,Paul Geiger,Noah T Kreski,T Scott Stroup

DOI: https://doi.org/10.1176/appi.ps.20240138

2024-09-23

Abstract:Objective: Current information on treatment and clinical characteristics of U.S. adults with schizophrenia spectrum disorders (i.e., schizophrenia, schizoaffective, and schizophreniform disorders) may help inform public health policy and service development for this population. Methods: Data were from the U.S. Mental and Substance Use Disorders Prevalence Study, conducted from October 2020 to October 2022. Clinicians administered the Structured Clinical Interview for the DSM-5 for past-year psychiatric and substance use disorder diagnoses among adults ages 18-65 years. Using sampling weights, the authors examined clinical and treatment characteristics among those with schizophrenia spectrum disorders and compared sociodemographic characteristics and comorbid behavioral health conditions of individuals with or without such disorders (N=4,764). Results: Among 114 adults with schizophrenia spectrum disorders, the most common comorbid conditions were major depressive episode (52%, 95% CI=34%-69%) and alcohol use (23%, CI=3%-43%), cannabis use (20%, 95% CI=1%-39%), and posttraumatic stress (17%, 95% CI=5%-30%) disorders. Global Assessment of Functioning scores were lower among people with than among those without schizophrenia spectrum disorders (mean±SE=44.8±2.0 vs. 77.2±0.5, p<0.01, respectively), indicating worse functioning. In the past year, 71% (95% CI=55%-87%) of adults with schizophrenia spectrum disorders received at least some mental health treatment, and 26% (95% CI=13%-38%) received minimally adequate treatment. Conclusions: Individuals with schizophrenia spectrum disorders face substantial challenges in the United States, including high rates of comorbid mental health conditions and substance use; few received adequate treatment. A strong social safety net and active clinical interventions are required to address the socioeconomic challenges and unmet mental health service needs of this population.
The Epidemiology of Drug Use Disorders Cross-Nationally: Findings from the WHO’s World Mental Health Surveys

Louisa Degenhardt,Chrianna Bharat,Meyer D. Glantz,Nancy A. Sampson,Kate Scott,Carmen C. W. Lim,Sergio Aguilar-Gaxiola,Ali Al-Hamzawi,Jordi Alonso,Laura H. Andrade,Evelyn J. Bromet,Ronny Bruffaerts,Brendan Bunting,Giovanni de Girolamo,Oye Gureje,Josep Maria Haro,Meredith G. Harris,Yanling He,Peter de Jonge,Elie G. Karam,Georges E. Karam,Andrzej Kiejna,Sing Lee,Jean-Pierre Lepine,Daphna Levinson,Victor Makanjuola,Maria Elena Medina-Mora,Zeina Mneimneh,Fernando Navarro-Mateu,Jose Posada-Villa,Dan J. Stein,Hisateru Tachimori,Yolanda Torres,Zahari Zarkov,Somnath Chatterji,Ronald C. Kessler,Mohammed Salih Al-Kaisy,Laura Helena Andrade,Corina Benjet,Guilherme Borges,Jose Miguel Caldas de Almeida,Grata Cardoso,Alfredo H. Cia,Koen Demyttenaere,John Fayyad,Silvia Florescu,Hristo Hinkov,Chi-yi Hu,Yueqin Huang,Aimee Nasser Karam,Norito Kawakami,Viviane Kovess-Masfety,John McGrath,Jacek Moskalewicz,Beth-Ellen Pennell,Marina Piazza,Kate M. Scott,Tim Slade,Juan Carlos Stagnaro,Margreet ten Have,Maria Carmen Viana,Harvey Whiteford,David R. Williams,Bogdan Wojtyniak

DOI: https://doi.org/10.1016/j.drugpo.2019.03.002

2019-01-01

Abstract:BackgroundIllicit drug use and associated disease burden are estimated to have increased over the past few decades, but large gaps remain in our knowledge of the extent of use of these drugs, and especially the extent of problem or dependent use, hampering confident cross-national comparisons. The World Mental Health (WMH) Surveys Initiative involves a standardised method for assessing mental and substance use disorders via structured diagnostic interviews in representative community samples of adults. We conducted cross-national comparisons of the prevalence and correlates of drug use disorders (DUDs) in countries of varied economic, social and cultural nature.Methods and findingsDSM-IV DUDs were assessed in 27 WMH surveys in 25 countries. Across surveys, the prevalence of lifetime DUD was 3.5%, 0.7% in the past year. Lifetime DUD prevalence increased with country income: 0.9% in low/lower-middle income countries, 2.5% in upper-middle income countries, 4.8% in high-income countries. Significant differences in 12-month prevalence of DUDs were found across country in income groups in the entire cohort, but not when limited to users. DUDs were more common among men than women and younger than older respondents. Among those with a DUD and at least one other mental disorder, onset of the DUD was usually preceded by the ‘other’ mental disorder.ConclusionsSubstantial cross-national differences in DUD prevalence were found, reflecting myriad social, environmental, legal and other influences. Nonetheless, patterns of course and correlates of DUDs were strikingly consistent. These findings provide foundational data on country-level comparisons of DUDs.
Comparing the Performance of World Mental Health Composite International Diagnostic Interview Substance Abuse Module in Adolescents to Diagnoses Made by Pediatric Addiction Medicine Specialists

Sharon Levy,Machiko Minegishi,Melissa Brogna,Geetha Subramaniam,Jennifer McCormack,Roger Weiss,Elissa R Weitzman,Elissa R. Weitzman

DOI: https://doi.org/10.1097/adm.0000000000001271

2024-03-15

Journal of Addiction Medicine

Abstract:Objectives The World Mental Health Composite International Diagnostic Interview Substance Abuse Module (WMH-CIDI-SAM) is commonly used as a criterion standard measure for substance use disorder (SUD) diagnoses, although the accuracy of this tool when used with adolescents is unknown. The objective of this study was to evaluate the agreement between SUD diagnoses for adolescents made by WMH-CIDI-SAM and those made by specialists based on Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) (DSM-5) SUD criteria during an SUD evaluation. Methods Adolescents aged 12 to 17 years presenting to an outpatient SUD program for youth were administered the WMH-CIDI-SAM by a trained research assistant, and results were compared with diagnoses made by experienced clinicians based on DSM-5 SUD criteria during an initial SUD evaluation. Chance-corrected concordance was estimated using the κ coefficient for the comparisons. Results The level of concordance between the WMH-CIDI-SAM interview and the clinician diagnosis based on DSM-5 SUD criteria were fair to moderate for alcohol use disorder and tobacco use disorder and poor for cannabis use disorder. Three of 11 WMH-CIDI-SAM item constructs showed poor concordance with clinician diagnosis. Conclusions Interpreting the diagnostic criteria for SUDs, particularly cannabis use disorders, is nuanced, and the meaning of the criteria may be misunderstood by adolescents. Further evaluation of the performance of the WMH-CIDI-SAM diagnostic interview for identifying cannabis use disorders in adolescents is needed.

substance abuse
Rates and correlates of dual diagnosis among adults with psychiatric and substance use disorders in a nationally representative U.S sample

Oluwole Jegede,Taeho Greg Rhee,Bin Zhou,Elina A. Stefanovics,Robert A. Rosenheck

DOI: https://doi.org/10.1016/j.psychres.2022.114720

IF: 11.3

2022-09-01

Psychiatry Research

Abstract:Treatment needs of adults diagnosed with both psychiatric and substance use disorders (i.e., dual diagnosis) have not received detailed characterization in a nationally representative US sample. Data from the National Epidemiologic Survey on Alcohol and Related Conditions Wave III were used to compare socio-behavioral, diagnostic, and service use characteristics of dually diagnosed adults to those with psychiatric disorders or SUDs alone. Adults with dual diagnosis were estimated to constitute 25.8% of those with any psychiatric disorder; 36.5% of those with any SUD and 17.8% of the 75.8 million adults with either disorder. Among those with psychiatric disorders, the independent correlates of dual diagnosis reflected substantial social or psychopathological disadvantages (e.g., violent behavior, poor mental health-related quality of life [HRQOL], police trouble, homelessness, and incarceration). Similarly, among those with SUD all independent correlates of dual diagnosis also reflected social or psychopathological disadvantages including poor mental HRQOL, witnessing trauma in childhood, childhood sex abuse, drug use diagnoses, suicide attempt, medical problems, having more than one SUD diagnosis, child neglect, repeated adult traumas, and less social support. Provision of medical, psychiatric, addiction and especially diverse social services in an integrated and accessible setting appear necessary and deserve further study.

psychiatry
Comparing Rates of Undiagnosed Hypertension and Diabetes in Patients With and Without Substance Use Disorders

Zoe Lindenfeld,Kevin Chen,Supriya Kapur,Ji E. Chang

DOI: https://doi.org/10.1007/s11606-024-08718-6

IF: 5.7

2024-03-13

Journal of General Internal Medicine

Abstract:Individuals with substance use disorders (SUDs) have increased risk for developing chronic conditions, though few studies assess rates of diagnosis of these conditions among patients with SUDs.

medicine, general & internal,health care sciences & services
Association of Cohort and Individual Substance Use With Risk of Transitioning to Drug Use, Drug Use Disorder, and Remission From Disorder: Findings From the World Mental Health Surveys

Louisa Degenhardt,Chrianna Bharat,Meyer D Glantz,Nancy A Sampson,Ali Al-Hamzawi,Jordi Alonso,Laura H Andrade,Brendan Bunting,Alfredo Cia,Giovanni de Girolamo,Peter De Jonge,Koen Demyttenaere,Oye Gureje,Josep Maria Haro,Meredith G Harris,Yanling He,Hristo Hinkov,Aimee Nasser Karam,Elie G Karam,Andrzej Kiejna,Viviane Kovess-Masfety,Victor Lasebikan,Sing Lee,Daphna Levinson,Maria Elena Medina-Mora,Zeina Mneimneh,Fernando Navarro-Mateu,Marina Piazza,José Posada-Villa,Kate Scott,Dan J Stein,Hisateru Tachimori,Nathan Tintle,Yolanda Torres,Ronald C Kessler,WHO World Mental Health Survey Collaborators

DOI: https://doi.org/10.1001/jamapsychiatry.2019.0163

2019-07-01

JAMA Psychiatry

Abstract:Importance: Limited empirical research has examined the extent to which cohort-level prevalence of substance use is associated with the onset of drug use and transitioning into greater involvement with drug use. Objective: To use cross-national data to examine time-space variation in cohort-level drug use to assess its associations with onset and transitions across stages of drug use, abuse, dependence, and remission. Design, setting, and participants: The World Health Organization World Mental Health Surveys carried out cross-sectional general population surveys in 25 countries using a consistent research protocol and assessment instrument. Adults from representative household samples were interviewed face-to-face in the community in relation to drug use disorders. The surveys were conducted between 2001 and 2015. Data analysis was performed from July 2017 to July 2018. Main outcomes and measures: Data on timing of onset of lifetime drug use, DSM-IV drug use disorders, and remission from these disorders was assessed using the Composite International Diagnostic Interview. Associations of cohort-level alcohol prevalence and drug use prevalence were examined as factors associated with these transitions. Results: Among the 90 027 respondents (48.1% [SE, 0.2%] men; mean [SE] age, 42.1 [0.1] years), 1 in 4 (24.8% [SE, 0.2%]) reported either illicit drug use or extramedical use of prescription drugs at some point in their lifetime, but with substantial time-space variation in this prevalence. Among users, 9.1% (SE, 0.2%) met lifetime criteria for abuse, and 5.0% (SE, 0.2%) met criteria for dependence. Individuals who used 2 or more drugs had an increased risk of both abuse (odds ratio, 5.17 [95% CI, 4.66-5.73]; P < .001) and dependence (odds ratio, 5.99 [95% CI, 5.02-7.16]; P < .001) and reduced probability of remission from abuse (odds ratio, 0.86 [95% CI, 0.76-0.98]; P = .02). Birth cohort prevalence of drug use was also significantly associated with both initiation and illicit drug use transitions; for example, after controlling for individuals' experience of substance use and demographics, for each additional 10% of an individual's cohort using alcohol, a person's odds of initiating drug use increased by 28% (odds ratio, 1.28 [95% CI, 1.26-1.31]). Each 10% increase in a cohort's use of drug increased individual risk by 12% (1.12 [95% CI, 1.11-1.14]). Conclusions and relevance: Birth cohort substance use is associated with drug use involvement beyond the outcomes of individual histories of alcohol and other drug use. This has important implications for understanding pathways into and out of problematic drug use.
The epidemiology of DSM-5 posttraumatic stress disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III

Risë B. Goldstein,Sharon M. Smith,S. Patricia Chou,Tulshi D. Saha,Jeesun Jung,Haitao Zhang,Roger P. Pickering,W. June Ruan,Boji Huang,Bridget F. Grant

DOI: https://doi.org/10.1007/s00127-016-1208-5

2016-04-22

Social Psychiatry and Psychiatric Epidemiology

Abstract:ObjectivesTo present current, nationally representative US findings on the past-year and lifetime prevalences, sociodemographic correlates, psychiatric comorbidity, associated disability, and treatment of DSM-5 posttraumatic stress disorder (PTSD).MethodsFace-to-face interviews with 36,309 adults in the 2012–2013 National Epidemiologic Survey on Alcohol and Related Conditions-III. PTSD, alcohol and drug use disorders, and selected mood, anxiety, and personality disorders were assessed using the Alcohol Use Disorder and Associated Disabilities Interview Schedule-5.ResultsPast-year and lifetime prevalences were 4.7 and 6.1 %, higher for female, white, Native American, younger, and previously married respondents, those with <high school education and lower incomes, and rural residents. PTSD was significantly associated with a broad range of substance use, mood, anxiety, and personality disorders, and past-month disability. Among respondents with lifetime PTSD, 59.4 % sought treatment; an average of 4.5 years elapsed from disorder onset to first treatment.ConclusionsDSM-5 PTSD is prevalent, highly comorbid, disabling, and associated with delayed help seeking. Additional research is needed to elucidate relationships identified herein, estimate PTSD-related costs, investigate hypotheses regarding etiology, course, and treatment, and support decisions about resource allocation to service delivery and research. Initiatives are needed to destigmatize PTSD, educate the public about its treatment, and encourage affected individuals to seek help.

psychiatry
The epidemiology of mental and substance use disorders in Australia 2020-22: Prevalence, socio-demographic correlates, severity, impairment and changes over time

Tim Slade,Joshua Vescovi,Cath Chapman,Maree Teesson,Vikas Arya,Jane Pirkis,Meredith G Harris,Philip M Burgess,Damian Santomauro,Siobhan O'Dean,Caley Tapp,Matthew Sunderland

DOI: https://doi.org/10.1177/00048674241275892

2024-09-08

Abstract:Objective: Mental and substance use disorders are the leading causes of disability worldwide. Contemporary estimates of prevalence, severity and impairment are essential for service planning. This study provides estimates of prevalence, severity, impairment and demographic correlates of mental and substance use disorders in 2020-22 and changes in prevalence since 2007. Methods: Data were from the two Australian National Surveys of Mental Health and Wellbeing conducted in 2020-22 (N = 15,893) and 2007 (N = 8841). Descriptive statistics report prevalence of lifetime and 12-month mental and substance use disorder by sex and age, proportion of people with each mental disorder by levels of severity (mild, moderate and severe) and mean days out of role by mental disorder class (mood, anxiety, substance use). Logistic regression analyses examined demographic correlates of mental disorder class and assessed changes over time. Results: The lifetime prevalence of any mental or substance use disorder in 2020-22 was 40.2%. The 12-month prevalence was 20.2% (mood disorder - 7.4%, anxiety disorder - 15.7% and substance use disorder - 3.1%). Mood disorders were associated with significant impairment. The prevalence of mental disorders has changed over time, with mood and anxiety disorders increasing and substance use disorders decreasing. These changes were most evident among young adults. Conclusion: Mental disorders are common in Australia. Impairment associated with mental disorders remains significant. Particular focus should be paid to young adults aged 16-24 years who have shown the largest increases in anxiety and mood disorder prevalence over the past 13 years.
Axis Ⅰ comorbidity of the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders among heroin-dependent patients

Mei YANG,Yan-hui LIAO,Qiang WANG,Hong WANG,Kavi VASISH,Tie-qiao LIU,Wei HAO

DOI: https://doi.org/10.3760/cma.j.issn.1006-7884.2013.01.003

2013-01-01

Abstract:Objective To provide lifetime rates of axis Ⅰ conorbidities of the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) among patients with heroin dependence.Methods A cross-section study was conducted.Subjects were 1002 heroin-dependent patients who were consecutively admitted into three drug rehabilitation settings in Hunan province.A questionnaire was developed to get demographic and drug use-related information of the subjects.Structured Clinical Interview for DSM-IV-TR Axis Ⅰ Disorders-Patient Edition (SCID-I/P) was used for making lifetime DSM-Ⅳ axis Ⅰ diagnoses.Results Among the subjects,mood disorder was the most common type of cooccurring axis Ⅰ non-substance use mental disorders (191,19.1％),followed by anxiety disorder (128,12.8％).Major depression (135,13.5％) was the most common diagnosis among co-occurring mood disorders,whereas post-traumatic stress disorder (PTSD,81,8.1％) was the most common diagnosis among anxiety disorders.579 (57.8％) subjects had other substance (non-opioid,other than tobacco) use disorders.The most frequent diagnoses of other substance use disorders were sedative-hypnotics use disorder and alcohol use disorder,with lifetime rates of 30.3％ (303) and 27.5％ (275) respectively,followed by stimulant and hallucinogen use disorder,with a lifetime rate of 14.8％ (148) for stimulant use disorder and a lifetime rate of 12.7％ (127) for hallucinogen use disorder.Conclusions Co-occurring non-substance use mental disorders and other substance use disorders among heroin-dependent patients in China are highly prevalent,to which great importance should be attached in the process of diagnosis and treatment.
Alcohol and drug use disorders in adult attention-deficit/hyperactivity disorder: Prevalence and associations with attention-deficit/hyperactivity disorder symptom severity and emotional dysregulation

Espen Anker,Jan Haavik,Trond Heir

DOI: https://doi.org/10.5498/wjp.v10.i9.202

2020-09-19

World Journal of Psychiatry

Abstract:BACKGROUND: High risk of alcohol and drug use disorders in people with attention-deficit/hyperactivity disorder (ADHD) calls for exploratory research of relationships with clinical features of ADHD.AIM: To estimate prevalence of alcohol/drug use disorders and associations with ADHD symptom severity and emotional dysregulation, in adults with ADHD.METHODS: This observational cross-sectional clinical study consisted of patients admitted to a private psychiatric outpatient clinic in Oslo, Norway (2014-2018). Five-hundred and fifty-eight eligible patients diagnosed with ADHD (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria) agreed to participate. Alcohol and drug use disorders were diagnosed using the Mini International Neuropsychiatric Interview (MINI). Dependence and abuse were merged into "use" disorder as in MINI version 7.0/DSM-5. Questions were related both to lifetime and the past 12-mo. ADHD severity was assessed by the Adult ADHD Self Report Scale (ASRS). Subdivisions of the ASRS questionnaire as inattentive items and hyperactive/impulsivity items were recorded separately. Emotional dysregulation was assessed by the eight-item version of Barkley's Current Behavior Scale - Self Report.RESULTS: The 12-mo prevalence was 5.3% for alcohol use disorder and 13.7% for drug use disorder. The lifetime prevalence was 12.0% for alcohol use disorder and 27.7% for drug use disorder. Men had higher rates of both alcohol use disorder and drug use disorder compared to women. The prevalence of drug use disorder was more than twice that of alcohol use disorder for both sexes. The drugs most participants reported having used were (in descending order): Amphetamine (19.1%), cannabis (17.1%), cocaine or ecstasy (7.4%), benzodiazepines (7.4%), and heroin or other opioids (2.9%). Lifetime drug use disorder was significantly associated with both hyperactivity-impulsivity symptoms and emotional dysregulation symptom severity. Lifetime alcohol use disorder, on the other hand, was not significantly associated with ADHD symptoms or emotional dysregulation when adjusted for gender and age.CONCLUSION: Patients with ADHD have a high lifetime prevalence of drug use disorder, which is associated with higher levels of hyperactivity-impulsivity symptoms and emotional dysregulation.

psychiatry
Prevalence, Patterns, and Correlates of Multiple Substance Use Disorders among Adult Primary Care Patients.

William S. John,He Zhu,Paolo Mannelli,Robert P. Schwartz,Geetha A. Subramaniam,Li-Tzy Wu

DOI: https://doi.org/10.1016/j.drugalcdep.2018.01.035

IF: 4.852

2018-01-01

Drug and Alcohol Dependence

Abstract:Background: Addressing multiple substance use disorders (SUDs) in primary care-based screening and intervention may improve SUD treatment access, engagement, and outcomes. To inform such efforts, research is needed on the prevalence and patterns of multiple SUDs among primary care patients. Methods: Data were analyzed from a sample of 2000 adult (aged >= 18) primary care patients recruited for a multisite National Drug Abuse Treatment Clinical Trials Network (CTN) study (CTN-0059). Past-year DSM-5 SUDs (tobacco, alcohol, and drug) were assessed by the modified Composite International Diagnostic Interview. Prevalence and correlates of multiple versus single SUDs were examined. Latent class analysis (LCA) was used to explore patterns of multiple SUDs. Results: Multiple SUDs were found among the majority of participants with SUD for alcohol, cannabis, prescription opioids, cocaine, and heroin. Participants who were male, ages 26-34, less educated, and unemployed had increased odds of multiple SUDs compared to one SUD. Having multiple SUDs was associated with greater severity of tobacco or alcohol use disorder. LCA of the sample identified three classes: class 1 (83.7%) exhibited low prevalence of all SUDs; class 2 (12.0%) had high-moderate prevalence of SUDs for tobacco, alcohol, and cannabis; class 3 (4.3%) showed high prevalence of SUD for tobacco, opioids, and cocaine. LCA-defined classes were distinguished by sex, age, race, education, and employment status. Conclusions: Findings suggest that primary care physicians should be aware of multiple SUDs when planning treatment, especially among adults who are male, younger, less educated, or unemployed. Interventions that target multiple SUDs warrant future investigation.
Latent Classes of Comorbid Substance Use and Internalizing and Externalizing Symptoms and Their Stability in U.S. Adults Over Time: Findings from the PATH Study Waves 1–3 (2013–2016)

Courtney T. Blondino Robert Perera Michael Neale Roxann Roberson-Nay Juan Lu Elizabeth C. Prom-Wormley a Division of Epidemiology,Department of Family Medicine and Population Health,Virginia Commonwealth University School of Medicine,Richmond,Virginia,USAb Department of Biostatistics,Virginia Commonwealth University School of Medicine,Richmond,VA,USAc Virginia Institute for Psychiatric and Behavioral Genetics,Virginia Commonwealth University,Richmond,VA,USA

DOI: https://doi.org/10.1080/10826084.2024.2424382

2024-12-04

Substance Use & Misuse

Abstract:Introduction The co-occurrence of mental disorder symptoms is common in people who use substances. It is unclear whether patterns of comorbidity in a population-based sample of adults are consistent with prior work. The study goal was to identify this comorbidity structure and evaluate its stability over time.

psychiatry,substance abuse,psychology
Co-occurring mental and substance use disorders in Australia 2020–2022: Prevalence, patterns, conditional probabilities and correlates in the general population

Matthew Sunderland,Joshua Vescovi,Cath Chapman,Vikas Arya,Meredith Harris,Philip Burgess,Christina Marel,Katherine Mills,Andrew Baillie,Maree Teesson,Tim Slade

DOI: https://doi.org/10.1177/00048674241284913

2024-10-12

Australian & New Zealand Journal of Psychiatry

Abstract:Australian &New Zealand Journal of Psychiatry, Ahead of Print. Background:Previous estimates from 2007 found that co-occurring mental and/or substance use disorders were a pervasive feature of Australia's mental health. Since that time there have been shifts and improvements in the conceptualisation and incorporation of co-occurring disorders in research and treatment settings. The current study provides up-to-date estimates on the prevalence of co-occurring mental and/or substance use disorders, highlights common patterns of co-occurrence, identifies significant correlates and examines any changes in the extent of co-occurring disorders since 2007.Methods:Data were from the two Australian National Surveys of Mental Health and Wellbeing conducted in 2020–2022 (N = 15,893) and 2007 (N = 8841). Descriptive statistics were estimated for the number of co-occurring conditions, correlations and pairwise conditional probabilities. Multinomial logistic and robust Poisson regressions were used to identify significant correlates and compare changes in co-occurring conditions across surveys.Results:Approximately 46% of people with a mental or substance use disorder in the past 12 months experienced two or more diagnosable conditions. There was little evidence to suggest that the prevalence of co-occurring disorders has changed since 2007 (Prevalence Ratio (PR) = 1.08, 95% CI = 0.98–1.18). Subgroup analysis indicated that those aged 16–24 years were significantly more likely to experience any co-occurrence in 2020–2022 compared with those aged 16–24 years in 2007 (PR = 1.44, 95% CI = 1.17–1.77).Conclusions:Co-occurring mental and substance use disorders remain endemic in Australia. Indeed, they appear to be increasingly problematic in younger, more recent cohorts. The results suggest that continued effort is needed to develop and implement transdiagnostic interventions that target broad contextual and/or societal factors.

psychiatry
Characteristics of Alcohol, Marijuana, and Other Drug Use Among Persons Aged 13–18 Years Being Assessed for Substance Use Disorder Treatment — United States, 2014–2022

Sarah Connolly,Taryn Dailey Govoni,Xinyi Jiang,Andrew Terranella,Gery P. Guy,Jody L. Green,Christina Mikosz

DOI: https://doi.org/10.15585/mmwr.mm7305a1

2024-02-10

MMWR Morbidity and Mortality Weekly Report

Abstract:This report describes self-reported reasons for drug and alcohol use among teens in the U.S.

public, environmental & occupational health
Substance Use, Suicidal Thoughts, and Psychiatric Comorbidities

Brenden Tervo-Clemmens,Jodi M. Gilman,A. Eden Evins,Kate H. Bentley,Matthew K. Nock,Jordan W. Smoller,Randi M. Schuster

DOI: https://doi.org/10.1001/jamapediatrics.2023.6263

2024-03-05

JAMA Pediatrics

Abstract:This cross-sectional study evaluates the dose-dependent association between alcohol, cannabis, and nicotine use and psychiatric symptoms among participants in the Substance Use and Risk Factor Survey and the Youth Risk Behavior Survey.

pediatrics

12-month Prevalence Estimates of Substance Use Disorders Using DSM-5 Versus DSM-IV Criteria Among U.S. Nonelderly Adults With Substance Use

DSM-5 Substance Use Disorders among Adult Primary Care Patients: Results from a Multisite Study.

Implications of the shift to DSM‐5 for alcohol use disorder prevalence estimates in the National Survey on Drug Use and Health

A Cross-National Examination of Differences in Classification of Lifetime Alcohol Use Disorder Between DSM-IV and DSM-5: Findings from the World Mental Health Survey

Mental and Substance Use Disorders Prevalence Study: Background and Methods

The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services

Characterizing Schizophrenia Spectrum Disorders: Results of the U.S. Mental and Substance Use Disorders Prevalence Study

The Epidemiology of Drug Use Disorders Cross-Nationally: Findings from the WHO’s World Mental Health Surveys

Comparing the Performance of World Mental Health Composite International Diagnostic Interview Substance Abuse Module in Adolescents to Diagnoses Made by Pediatric Addiction Medicine Specialists

Rates and correlates of dual diagnosis among adults with psychiatric and substance use disorders in a nationally representative U.S sample

Comparing Rates of Undiagnosed Hypertension and Diabetes in Patients With and Without Substance Use Disorders

Association of Cohort and Individual Substance Use With Risk of Transitioning to Drug Use, Drug Use Disorder, and Remission From Disorder: Findings From the World Mental Health Surveys

The epidemiology of DSM-5 posttraumatic stress disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III

The epidemiology of mental and substance use disorders in Australia 2020-22: Prevalence, socio-demographic correlates, severity, impairment and changes over time

Axis Ⅰ comorbidity of the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders among heroin-dependent patients

Alcohol and drug use disorders in adult attention-deficit/hyperactivity disorder: Prevalence and associations with attention-deficit/hyperactivity disorder symptom severity and emotional dysregulation

Prevalence, Patterns, and Correlates of Multiple Substance Use Disorders among Adult Primary Care Patients.

Latent Classes of Comorbid Substance Use and Internalizing and Externalizing Symptoms and Their Stability in U.S. Adults Over Time: Findings from the PATH Study Waves 1–3 (2013–2016)

Co-occurring mental and substance use disorders in Australia 2020–2022: Prevalence, patterns, conditional probabilities and correlates in the general population

Characteristics of Alcohol, Marijuana, and Other Drug Use Among Persons Aged 13–18 Years Being Assessed for Substance Use Disorder Treatment — United States, 2014–2022

Substance Use, Suicidal Thoughts, and Psychiatric Comorbidities